Your browser is no longer supported. Please, upgrade your browser.
CNAT Conatus Pharmaceuticals Inc. daily Stock Chart
CNAT [NASD]
Conatus Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own3.34% Shs Outstand33.04M Perf Week-7.89%
Market Cap10.80M Forward P/E- EPS next Y-0.25 Insider Trans0.00% Shs Float32.24M Perf Month-3.68%
Income-12.60M PEG- EPS next Q-0.09 Inst Own16.10% Short Float5.12% Perf Quarter9.00%
Sales28.60M P/S0.38 EPS this Y2.60% Inst Trans-0.06% Short Ratio2.44 Perf Half Y-63.20%
Book/sh0.66 P/B0.50 EPS next Y32.40% ROA-32.80% Target Price1.60 Perf Year-93.65%
Cash/sh0.69 P/C0.48 EPS next 5Y38.00% ROE-51.70% 52W Range0.25 - 5.24 Perf YTD-81.10%
Dividend- P/FCF- EPS past 5Y1.00% ROI-66.70% 52W High-93.76% Beta2.12
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low30.80% ATR0.02
Employees30 Current Ratio6.10 Sales Q/Q-55.80% Oper. Margin-46.00% RSI (14)41.27 Volatility4.05% 6.29%
OptionableYes Debt/Eq0.00 EPS Q/Q35.50% Profit Margin-43.90% Rel Volume0.39 Prev Close0.33
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume674.80K Price0.33
Recom3.00 SMA20-6.01% SMA50-5.04% SMA200-62.18% Volume263,353 Change-0.94%
Dec-06-18Downgrade Stifel Buy → Hold
Feb-08-18Initiated ROTH Capital Buy $20
Nov-02-17Reiterated H.C. Wainwright Buy $18 → $17
Mar-16-17Reiterated Stifel Buy $7 → $9
Dec-20-16Reiterated Stifel Buy $5 → $7
Dec-20-16Reiterated H.C. Wainwright Buy $9 → $18
Nov-09-16Reiterated Stifel Buy $6 → $5
Jul-01-16Resumed ROTH Capital Buy
Nov-05-15Reiterated Stifel Buy $11 → $9
Sep-22-15Initiated H.C. Wainwright Buy $15
Apr-28-15Initiated Brean Capital Buy $13
Mar-17-15Resumed ROTH Capital Buy $15
Mar-12-15Reiterated Stifel Buy $13 → $11
Jan-09-15Reiterated ROTH Capital Buy $19 → $12
Oct-21-14Initiated MLV & Co Buy $16
Aug-14-14Reiterated Stifel Buy $14 → $13
Aug-19-13Initiated Stifel Buy $16
Nov-05-19 07:15PM  Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM  Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-03-19 08:22AM  Is Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) CEO Paid Enough Relative To Peers? Simply Wall St.
Oct-31-19 10:35AM  Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-11-19 12:02PM  Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes Zacks
09:59AM  Penumbra Enrolls First Patient for Study on Coronary Vessels Zacks
Sep-19-19 10:29AM  How Long Will Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) Cash Last? Simply Wall St.
Sep-10-19 09:21AM  Top Ranked Momentum Stocks to Buy for September 10th Zacks +6.65%
Aug-19-19 09:00AM  Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know Zacks
Aug-07-19 11:00AM  Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies Zacks -5.30%
Aug-06-19 07:25PM  Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates GlobeNewswire
Jul-31-19 10:36AM  Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-25-19 01:46PM  Investors Who Bought Conatus Pharmaceuticals (NASDAQ:CNAT) Shares Five Years Ago Are Now Down 96% Simply Wall St. -12.16%
Jun-26-19 04:17PM  Conatus (CNAT) Stock Price Could Hit Zero SmarterAnalyst
08:37AM  Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More Zacks
07:19AM  The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart Benzinga
06:07AM  Conatus' Emricasan Lags Primary Goal in Liver Function Study Zacks
Jun-25-19 11:32AM  NASH Disappointment Forces Conatus To Explore Strategic Alternatives Benzinga -68.54%
Jun-24-19 05:00PM  UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial Reuters
04:19PM  Conatus Pharma to explore options, liver disease drug fails trial Reuters
04:06PM  Conatus to Explore Strategic Alternatives and Implement Restructuring Plan GlobeNewswire
04:05PM  Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis GlobeNewswire
Jun-12-19 06:27PM  CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Zacks
Jun-01-19 09:31AM  Conatus (CNAT) Down 5.8% Since Last Earnings Report: Can It Rebound? Zacks
May-28-19 11:48AM  Conatus Down More Than 60% in the Past 90 Days: Here's Why Zacks
May-24-19 09:39AM  How Many Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Shares Do Institutions Own? Simply Wall St.
May-06-19 02:53PM  Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1 Zacks
May-02-19 07:15PM  Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:11PM  Conatus: 1Q Earnings Snapshot Associated Press
Apr-30-19 07:30AM  Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis GlobeNewswire
Apr-24-19 10:33AM  Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-15-19 07:30AM  Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension GlobeNewswire -34.42%
Apr-07-19 05:04PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
09:30AM  Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report? Zacks
Apr-02-19 07:30AM  Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference GlobeNewswire +17.24%
Mar-27-19 10:55AM  Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks -5.79%
Mar-22-19 05:43PM  Conatus (CNAT) Declines on Failure of NASH Fibrosis Study Zacks -56.01%
10:49AM  Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo Benzinga
Mar-21-19 04:05PM  Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis GlobeNewswire
Mar-20-19 11:10AM  Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan Zacks
Mar-14-19 06:09PM  Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 10:35AM  Implied Volatility Surging for Conatus (CNAT) Stock Options Zacks +25.65%
09:00AM  Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension GlobeNewswire
Mar-11-19 10:57AM  Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus Zacks +6.60%
Mar-08-19 04:05PM  Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates GlobeNewswire
Mar-01-19 07:30AM  Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire +9.28%
Feb-25-19 01:20PM  Is Conatus Pharmaceuticals Inc.s (NASDAQ:CNAT) CEO Pay Justified? Simply Wall St.
Feb-13-19 03:36PM  Conatus (CNAT) Completes Enrollment in Phase II NASH Study Zacks
Feb-12-19 07:30AM  Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis GlobeNewswire
Jan-30-19 08:05AM  Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals ACCESSWIRE +6.98%
Jan-29-19 10:05AM  Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings? Zacks +22.86%
Jan-28-19 07:30AM  Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials GlobeNewswire
Dec-28-18 05:40PM  Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan Zacks
Dec-13-18 09:26AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis Zacks -5.59%
Dec-12-18 10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
Dec-07-18 08:04AM  The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut Benzinga -11.86%
Dec-06-18 02:51PM  Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study Zacks -56.89%
02:13PM  Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint MarketWatch
07:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis ACCESSWIRE
Dec-05-18 07:30AM  Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis GlobeNewswire
Nov-16-18 10:42AM  When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable? Simply Wall St.
07:50AM  Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Nov-14-18 08:46AM  Do Options Traders Know Something About Conatus (CNAT) Stock We Don't? Zacks -6.67%
Nov-09-18 05:28PM  Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents -6.81%
Nov-08-18 07:30AM  Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting GlobeNewswire +8.73%
Nov-05-18 07:00AM  Todays Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals ACCESSWIRE
Nov-02-18 12:30PM  Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates Zacks +19.63%
07:30AM  Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:03AM  Conatus: 3Q Earnings Snapshot Associated Press
Nov-01-18 04:05PM  Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates GlobeNewswire
Oct-25-18 07:30AM  Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results GlobeNewswire
Oct-11-18 08:51AM  Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock Zacks
Oct-02-18 04:05PM  Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting GlobeNewswire
Sep-25-18 08:00AM  Conatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Target ACCESSWIRE -7.70%
Sep-20-18 07:30AM  Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension GlobeNewswire +17.37%
Sep-19-18 08:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and INSYS Therapeutics ACCESSWIRE
07:30AM  Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-18-18 10:50AM  Who Owns Most Of Conatus Pharmaceuticals Inc (NASDAQ:CNAT)? Simply Wall St. +12.98%
Aug-31-18 09:58AM  Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock Zacks
09:49AM  Conatus (CNAT) Up 36.2% Since Last Earnings Report: Can It Continue? Zacks
Aug-29-18 07:30AM  Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference GlobeNewswire
Aug-23-18 08:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE +6.78%
Aug-03-18 05:14PM  Edited Transcript of CNAT earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 11:47AM  Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally Zacks
Aug-01-18 08:20PM  Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:15PM  Conatus: 2Q Earnings Snapshot Associated Press
04:05PM  Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates GlobeNewswire
Jul-30-18 12:15PM  What's in the Cards for Conatus (CNAT) This Earnings Season? Zacks
Jul-25-18 04:05PM  Conatus Pharmaceuticals to Report Second Quarter 2018 Financial Results GlobeNewswire
Jul-02-18 07:30AM  Conatus Pharmaceuticals Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis GlobeNewswire +6.78%
Jun-14-18 09:23AM  NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
Jun-01-18 10:20AM  Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report? Zacks
May-03-18 11:58AM  Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates Zacks -5.43%
May-02-18 06:22PM  Conatus: 1Q Earnings Snapshot Associated Press
04:05PM  Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates GlobeNewswire
Apr-30-18 07:30AM  Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension GlobeNewswire
Apr-27-18 11:50AM  What's in the Cards for Conatus (CNAT) This Earnings Season? Zacks
Apr-25-18 04:05PM  Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results GlobeNewswire +9.70%
Apr-18-18 07:30AM  Conatus Pharmaceuticals IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo GlobeNewswire
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.